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ABSTRACT
Major histocompatibility complex class II mRNAs
encode heterodimeric proteins involved in the pres-
entation of exogenous antigens during an immune
response. Their 30UTRs bind a protein complex in
which we identified two factors: EBP1, an ErbB3
receptor-binding protein and DRBP76, a double-
stranded RNA binding nuclear protein, also known
as nuclear factor 90 (NF90). Both are well-
characterized regulatory factors of several mRNA
molecules processing. Using either EBP1 or
DRBP76/NF90-specific knockdown experiments,
we established that the two proteins play a role in
regulating the expression of HLA-DRA, HLA-DRB1
and HLA-DQA1 mRNAs levels. Our study represents
the first indication of the existence of a functional
unit that includes different transcripts involved in
the adaptive immune response. We propose that
the concept of ‘RNA operon’ may be suitable for
our system in which MHCII mRNAs are modulated
via interaction of their 30UTR with same proteins.
INTRODUCTION
Major histocompatibility complex class II molecules
(MHCII) are cell-surface glycoproteins that have a
central role in the adaptive immune response because
they present peptides, mainly derived from extracellular
proteins, to the antigen receptor of CD4
+ T cells (1).
The MHCII molecules are expressed by professional
antigen-presenting cells (APCs) that are cells of haemato-
poietic origin, such as dendritic cells (DCs), B lympho-
cytes and cells of the monocyte/macrophage lineage.
These professional APCs are able to induce both
primary and secondary immune responses because of
the constitutive expression of MHCII molecules, as well
as of potent costimulatory molecules, differently than
non-professional APCs. The latter deﬁnition includes
non-bone marrow-derived cells that do not express a
complete range of costimulatory molecules, constitutively
expressing MHCII molecules, such as thymic epithelial
cells and endothelial cells in various organs, as well as
cell types that do not express basal levels of MHCII mol-
ecules but can be induced to express MHCII molecules in
response to IFNg and some tumour cells from several
neoplastic tissues (2,3)
MHCII molecules are composed of two non-covalently
associated polypeptides, a- and b-chains, encoded by dif-
ferent genes located on the short arm of chromosome 6.
MHCII is a multigenic system including different isotypes
(HLA-DR, HLA-DP and HLA-DQ), whose expression is
cell-type regulated at the transcription level by a highly
conserved MHCII enhanceosome (4). The functioning of
the immune response in infection, transplantation and
autoimmunity is strictly dependent on the level of expres-
sion of MHCII molecules on the APC surface (5), which
regulate the efﬁcacy of antigen presentation. Moreover,
MHCII expression level in cancer cells seems to correlate
with increased tumourigenicity, metastatic potential and
reduced immunogenicity (3,6). One of the elements that
inﬂuences the density of these molecules is certainly the
difference in the regulation of transcription demonstrated
for DQB1 (7), DRB1 (8) and DQA1 (9,10) genes. It has
been suggested that this variability is caused by an allelic
polymorphism in the 50 regulatory region and contributes
to the difference in susceptibility to autoimmune disease in
different individuals (11). Other evidence indicates that the
post-transcriptional regulation is yet another level of
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variability of cis-sequences located in the 50 and 30UTR of
MHCII mRNAs encoded by different alleles by binding
trans-acting factors could also inﬂuence their expression
and play a role in the antigen presentation.
It has been shown that the inhibition of protein synthe-
sis results in a signiﬁcant reduction of the half-life of all
MHCII mRNAs studied (14) by a mechanism in which
ongoing translation per se is required for the stabilization
of the transcripts (15). A sequence of HLA-DRA mRNA
able to bind nuclear and cytoplasmic protein factors has
been previously identiﬁed in the 30UTR region (16). Its
ability to cross-compete with HLA-DQA1 mRNA for
complex formation suggests that different 30UTR of
MHCII mRNAs share consensus sequences or secondary
structures able to interact with ribonucleoproteins
(RNPs). The 30UTRs and the 50UTRs are the transcript
target sequences involved in the RNPs binding, inside the
‘RNA operon’ (17–19). This is a functional unit in which
multiple physiologically related transcripts can be
co-ordinately regulated during splicing, export, stability,
localization and translation. These subpopulations of
mRNAs bind the same RNP complex in a dynamic
manner because the protein components could change
during the different steps of the RNA processing and
each mRNA can join different RNA operons.
Many studies have conﬁrmed that the expression of
proteins involved in immune-mediated inﬂammation is
modulated by a ‘post-transcriptional operon’ (20,21). In
this framework, the stabilities (22,23) of distinct groups of
mRNAs change in a co-ordinate way in order to efﬁciently
produce functional protein groups according to the cell
needs. For example, Human antigen R (HuR) (24,25)
and tristetraproline (TTP) (26), in activated T lympho-
cytes and in cancer cells, respectively, are able to
modulate the half-lives of many common mRNA targets
including cytokines and chemokines that must be syn-
chronously regulated during the immune response.
In the current study, we present data relative to the
identiﬁcation and characterization of two proteins
participating in the complex that interacts with the
30UTR of MHCII mRNAs. Our data suggest that these
factors play a role in the RNA expression, consistent with
the ‘RNA operon model’ in which functionally related
transcripts such as MHCII mRNAs are regulated by the
same RNPs.
MATERIALS AND METHODS
Cell lines
The M14 cell line was established from specimens
obtained by primary tumours from melanoma patients
(27) and was cultured in RPMI medium 1640 with 10%
FCS (GIBCO) and 1% penicillin/streptomycin (SIGMA).
Raji is a B lymphoma cell line and was cultured in RPMI
with 10% FCS (GIBCO) and 1% penicillin/streptomycin
(SIGMA).
Flow cytometry analysis
Determination of cell surface expression of MHCII
antigens was performed by cytoﬂuorimetric analysis
using the FACS ARIA cell-sorting system and analysed
by the DIVA software (BD Biosciences). FITC mouse
anti-human HLA-DR, along with the appropriate FITC
mouse IgG isotype controls were purchased from BD
Biosciences. Cell cycle analysis was performed following
propidium iodide staining and ﬂow cytometry analysis.
In Vitro transcription
All DNA fragments used for the riboprobe synthesis were
obtained by PCR, using full length cDNAs as template
and the primers indicated in Table 1. The transcription
reactions were performed to obtain cold and [
32P] UTP
labelled probes using T7 in vitro transcription system
MAXIScript T7 (Ambion).
RNA electrophoretic mobility shift assay (REMSA) and
supershift
S100 protein extracts were obtained from M14 melanoma
cells, lysed with ﬁve cell volumes of hypotonic buffer:
10mM HEPES pH 7.9, 1.5mM MgCl2, 10mM KCl,
0.5mM DTT, 0.2mM PMSF, 1xPI (protease inhibitors
cocktail). The extracts were centrifuged at 1000g and the
supernatant was mixed with 0.11 volumes of S100 extrac-
tion buffer (0.3M HEPES pH 7.9; 30mM MgCl2; 1.4M
KCl; 1xPI). After centrifugation at 100000g, the samples
were dialysed against 50 volumes of dialysis buffer: 20mM
HEPES pH 7.9, 20% glycerol, 100mM KCl, 0.5mM
DTT, 0.2mM EDTA. REMSAs were performed as
described previously (16). In brief, 30mg protein was
incubated for 30min at room temperature with 5 10
5
cpm of
32P-UTP-labelled 3-DRA or 3-DQA1 riboprobes.
Differently 3-DRB1 and 3-DQB1 riboprobes were
refolded by heating to 70 C for 5min and slow-cooling
to room temperature over 1h before use in binding experi-
ments (28). After incubation, the reaction mixtures were
treated with 10 U RNase T1 to digest the RNA sequences
unprotected by the complex binding and with heparin at a
ﬁnal concentration of 5mg/ml, at 22 C. Competition
assays were performed by pre-incubating 0.5 and 5mgo f
cold probe and 0.5 and 5mg of poly(U) or poly(G) or
poly(C) or poly(A) homopolymers (SIGMA) with the
protein extract prior to the incubation with the
radio-labelled riboprobes. For antibody supershift assays
0.5, 2 and 6mg of speciﬁc polyclonal rabbit anti-EBP1
(UPSTATE Cell Signalling) and monoclonal mouse
anti-DRBP76 (Biosciences Pharmigen) or 6mg control
IgG were pre-incubated with cell extracts prior to the
addition of probes. The binding reactions with 3-DRA
or 3-DQA1 and 3-DRB1 or 3-DQB1 riboprobes were
separated on native 6% or 5% PAGE, respectively. The
gels were subsequently dried and radioactive image
acquired by Typhoon analysis (Amersham Bioscience).
RNA interference-mediated gene silencing
Transfections of siRNA for gene silencing were performed
using HiPerFect Transfection Reagent (QIAGEN). The
7264 Nucleic Acids Research, 2011,Vol.39, No. 16siRNAs used in this study were all purchased from
QIAGEN and were those showing the highest and more
speciﬁc interference potential against the intended targets,
chosen in the list of pre-designed siRNAs. The target se-
quences of siRNA used are listed in Table 1. Brieﬂy, cells
were plated at 3 10
5 cells/well in six-well plates and
incubated for 24h before performing transfection with
50nM siRNAs concentration. Cells were collected by
trypsinization at 0, 24, 48 and 72h after the transfection
for both ﬂow cytometry and cell cycle analysis and for
RNA isolation.
Quantitative measurement of speciﬁc transcripts by
qRT–PCR assay
For the isolation of total RNA, after the cells were lysed in
the QIAzol Lysis Reagent (QIAGEN), the RNA was
puriﬁed using phenol–chloroform extraction. All reverse
transcriptase reactions were performed using the
QuantiTect RT Kit (QIAGEN). The accumulation of
speciﬁc transcripts was measured by qRT–PCR, using
the DNA Engine Opticon Real-Time PCR Detection
System (BIORAD). The qRT–PCR assays were per-
formed using the amount of cDNA obtained retro-
transcribing 0.5mg of total RNA. The QuantiTect SYBR
Green PCR Kit (QIAGEN) was used to perform all the
reactions in presence of 0.2mM primers (Table 1),
synthesized by PRIMM; each assay was run in triplicate.
The relative amount of speciﬁc transcripts was calculated
by the comparative cycle threshold method given by Livak
and Schmittgen (29). To correct for sample to sample vari-
ations in qRT–PCR efﬁciency and errors in quantization,
the level of GAPDH transcripts was tested for use in nor-
malization of speciﬁc RNA levels. External standards
were used to establish standard PCR curves for quantify-
ing copies of those transcripts that required an absolute,
comparative quantization. In the graphs, we report the
mRNA fold variation as the ratio of the measured value
for an experimental sample to the value for the control
sample, when the control is equal to 1.
Northwestern blot (NW) and western blot (WB) assays
Extracts were separated on 12.5% SDS–PAGE and
electrotransferred to PVDF membrane (Amersham). For
NW membrane-bound proteins were sequentially
immersed at 22 C in binding buffer 1 (BB1; 50mM
Tris–HCl, pH 7.5, 50mM NaCl, 1mM EDTA, 1mM
DTT) containing decreasing concentrations of guan-
idine–HCl (5min each in 6M, 3M, 1.5M, 0.75M,
Table 1. Sequences of primers used for riboprobes template synthesis, target sequences of siRNA and sequences of primers used for qRT–PCR,
respectively
Probe Primers Sequence
Primers used for PCR of riboprobes templates
3-DRA 3DRAT7 TAATACGACTCACTATAGGACATGGAGGTGATGGTGTTTC
3DRAR TTCCACCCAAGATCATCAAA
3-DQA1 3DQA1T7 TAATACGACTCACTATAGGCCATCCTGGAAGGGAAGTG
3DQA1R TCAGGAGGTCAGGGAAAGAA
3-DRB1 3DRB1T7 TAATACGACTCACTATAGGAATGCAGATGACCACATTCAAG
3DRB1R TGAGAAACATTTAATAATGTAATG
3-DQB1 3DQB1T7 TAATACGACTCACTATAGGGCACTGACTCCTGAGACTATT
3DQB1R TGCTTCTCTTGAGCAGTCTGAG
GFP GFPT7 TAATACGACTCACTATAGGAAGAGTGCCATGCCCGAAGGT
GFPR GCTGCTGGGATTACACATGGC
siRNA target sequences
siNF90 50-GCCCACCTTTGCTTTTTAT-30
siEBP1 50-TCCCACCAGCATTTCGGTAAA-30
siDRA 50-CAGGAATCATGGGCTATCAAA-30
siDRB1 50-CCTGGACAGATACTTCTATAA-30
Primers used for qRT–PCR
b-Actin ACT-F TCATGAAGTGTGACGTTGACA
ACT-R CCTAGAAGCATTTGCGGTGCAC
GAPDH G-F AACGGATTTGGTCGTATTGGGC
G-R TCGCTCCTGGAAGATGGTGATG
HLA-DRA DRA-F GGACAAAGCCAACCTGGAAA
DRA-R AGGACGTTGGGCTCTCTCAG
HLA-DRA 30UTR 3DRA-F ACATGGAGGTGATGGTGTTT
3DRA-R AGCCAGCTAGATGTTAGAGTACG
HLA-DRB1 DRB1-F CTCAGCATCTTGCTCTTGTGCAG
DRB1-R CAGCATTAAAGTCAGGTGGTTCC
HLA-DQA1 DQA1-F GGTGTAAACTTGTACCAGT
DQA1-R GGAGACTTGGAAAACACT
HLA-A-B-C MHCI_F CTCAGCATCTTGCTCTTGTGCAG
MHCI_R ATGTAATCCTTGCCGTCGTA
EBP1 EBP1-F CTGCACGCCAATAGAAGG
EBP1-R AGTAAACGGCATGGCATCA
DRBP76/NF90 NF90-F CTGGTGCTGCTGTGTAAGGA
NF90-R AGGGACAATGGAGGCTCTTT
The underlined sequence represents the T7 promoter.
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rinsed in BB1 and blocked for 1h in 2.5% nonfat milk
powder. RNA binding was carried out in BB1 containing
150000 cpm/ml of the corresponding labelled RNA probe
(50–100ng/ml) and 10mg/ml each of yeast RNA for 2h at
22 C. After three washes in BB1, bound labelled RNA
was detected by Typhoon analysis (Amersham
Bioscience) (30). The RNA binding protein used as
negative control was hnRNPH1 (31).
In western blot analysis, we used mouse monoclonal
anti-DRBP76 (Biosciences Pharmigen) and rabbit poly-
clonal anti-EBP1 antibodies. After incubation with
goat anti-rabbit secondary antibody, all membranes were
developed using ECL kit (Amersham Bioscience) and
exposed to X-ray ﬁlm. EBP1 expression plasmid encoding
the larger p48 isoform of the protein was kindly provided
by Professor S. Curry and recombinant protein was
prepared according to the published protocol (28).
Protein biochemical puriﬁcation
Heparin-sepharose CL-6B (GE-Healthcare) was swelled
in distilled water and then equilibrated in buffer A:
10mM HEPES pH 7.5, 40mM KCl, 3mM MgCl2 and
5% glycerol. About 80mg of Raji S100 extract was
incubated in batch with heparin-sepharose resin.
Thereafter the bound resin was packed in a small
column. Non-adsorbed proteins were washed out with
Buffer A and bound proteins were eluted with four
10ml steps of KCl in Buffer A (0.25M; 0.5M; 0.75M
and 1.0M). For each step, 10 fractions (500ml) were re-
covered. The absorbance reading at 280nm allowed us to
see two peaks (a and b) as shown in Figure 3, panel A. The
peaks obtained from the columns were pooled separately
and dialysed against 50 volumes of Buffer A (20mM Tris–
HCl pH 8.0, 0.1mM EDTA, 0.1mM DTT). About 30mg
of these heparin binding fractions were checked for
binding activity by REMSA using 3-DRA labelled probe
(data not shown).
Pooled fractions of peak b were subsequently separated
by FPLC Mono Q anion-exchange chromatography. The
column was washed with Mono Q buffer A (20mM Tris–
HCl pH 8.0, 0.1mM EDTA, 0.1mM DTT) and eluted
with a ﬁrst linear gradient from 0% to 50% of Mono Q
buffer B (1M NaCl in Mono Q buffer A) and a second
linear gradient from 50% to 100% of Mono Q buffer B
(Figure 3, panel B). Each fraction was analysed by
northwestern blot.
Poly(U)-Sepharose 4-B (GE-Healthcare) was swelled in
distilled water for 15min. The resin was packed in a 2ml
column and then equilibrated in Buffer 1 containing
20mM Tris–HCl pH 7.5, 0.1mM EDTA pH 8.0,
0.1mM DTT and 50mM NaCl. A quantity of 6mg of
Raji S100 extract was loaded into the column and
non-adsorbed proteins were washed out with 30 volumes
of Buffer 1. Bound proteins were eluted with Buffer 2
(20mM Tris–HCl pH 7.5, 0.1mM EDTA pH 8.0,
0.1mM DTT and 500mM NaCl recovering 10 fractions
that were subsequently separated by FPLC Mono Q
anion-exchange chromatography. Each fraction was
analysed by northwestern blot using 3-DRA probes and
the bands of binding analysed by nano-Electrospray
Ionization Tandem Mass Spectrometry (nano-ESI-MS/
MS) (data not shown).
Nano-ESI–MS/MS
The bands resulting from the puriﬁcation procedure and
identiﬁed by RNA binding activity assay as containing
protein of interest were excised and subjected to in situ
digestion with trypsin by using the procedure as described
(in Protein Chip Technical note). Extracted peptides were
separated by nano-HPLC (Dionex Ultimate) and
sequenced online by nano-ESI MS/MS experiments with
a Q-TOF mass spectrometer (Q-Star Elite; Applied
Biosystems). Sequences were searched with the Mascot
algorithm in the NCBInr database (human). Only
peptides with individual ion scores >41 indicating
identity or extensive homology (P<0.05) were taken
into account (Table 2).
RESULTS
Identiﬁcation of cytoplasmic proteins binding to the
30UTR of MHCII mRNAs in a non-professional APC
There is evidence that in Raji, a B lymphoma cell line
acting as a professional APC, the 30UTR of HLA-DRA
and HLA-DQA1-speciﬁc mRNAs bind to factors exhibit-
ing different subcellular locations (16). To better appreci-
ate any variation in the expression of MHCII genes due to
the manipulation of these interactions, we chose a cell
model system showing a low constitutive expression of
MHCII molecules and representing a non-professional
APC, the M14 melanoma cell line derived from primary
human melanoma (27).
Table 2. Sequences of peptides obtained by nano-ESI-MS/MS of
proteins extracted from polyacrylamide gel after in situ trypsin
digestion
Peptides identiﬁed Mass Amino
acid
position
EBP1 identiﬁcation
SDQDYILK 9.804.815 93–100
LVKPGNQNTQVTEAWNK 19.259.959 155–171
TIIQNPTDQQK 12.846.674 199–209
AFFSEVER 9.834.712 263–270
FDAMoxPFTLR 11.125.325 271–280
RFDAMoxPFTLR 12.686.336 270–280
HELLQPFNVLYEKEGEFVAQFK 26.823.693 298–319
HELLQPFNVLYEK 16.288.562 298–310
EGEFVAQFK 10.535.131 311–319
FTVLLMPNGPMR 14.067.050 320–331
FTVLLMoxPNGPMoxR 14.067.050 320–331
ITSGPFEPDLYK 13.656.816 332–343
SEMoxEVQDAELK 12.935.758 344–354
ALLQSSASRK 9.315.087 355–364
DRBP76/NF90 identiﬁcation
LFPDTPLALDANK 14.137.504 49–66
SSELEQYLQR 12.516.095 427–436
VLAGETLSVNDPPDVLDR 19.089.793 458–470
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the stop codon, were designed to analyse the cytoplasmic
protein binding with 30UTR of MHCII mRNAs: 3-DRA
corresponding to a 403bp fragment of HLA-DRA cDNA;
3-DRB1 equivalent to a 308bp fragment of HLA-DRB1
cDNA; 3-DQA1, corresponding to a 202bp sequences of
HLA-DQA1 cDNA; and 3-DQB1, equivalent to a 295bp
sequences of HLA-DQB1 cDNA (Figure 1, panel A).
3-DRA and 3-DRB1 are the full-length 30UTRs (except
for few bases), 3-DQB1 is the region upstream the ﬁrst
poly(A) signal and 3-DQA1 is the minimum binding site
common to all splicing variants (32).
Binding assays were carried out using S100 extracts
from both M14 and Raji cell lines to investigate also on
the possible tissue speciﬁcity of the interactions. First, we
performed northwestern blot analysis using 3-DRA and
3-DQA1 riboprobes and observed a similar pattern of
binding with proteins from two cell lines immobilized on
the membrane (Figure 1, panel B). The negative control
was performed by using a GFP labelled riboprobe that
showed no interaction band (data not shown). Then we
carried out REMSA experiments that clearly conﬁrmed
the interaction between proteins present in the S100 cyto-
plasmic extracts from M14 and either 3-DRA (lane 5)
or 3-DQA1 (lane 10) riboprobes (Figure 2, panel A).
Speciﬁcity of the binding was assessed by competition
experiments using unlabelled probes (lanes 6 and 7 for
3-DRA; lanes 13 and 14 for 3-DQA1). In addition, 0.5
and 5mg of cold 3-DQA1 completely displaced the
binding activity to 3-DRA probe (lanes 8 and 9) and
the same amount of cold 3-DRA was able to compete
totally with the binding to 3-DQA1 (lanes 11 and 12).
The binding activity with 3-DRB1 and 3-DQB1was not
observed with the protocol used for the previous experi-
ment. However, it became apparent after riboprobes
heating to 70 C for 5min and slow-cooling to room tem-
perature (Figure 2, panel B, lanes 27 and 32). About 0.5
and 5mg of both cold 3-DRA (lanes 25 and 26) and
3-DQA1 (lanes 28 and 29) completely displaced the
binding activity to 3-DRB1 probe. The same amount of
cold 3-DRA (lanes 30 and 31) or 3-DQA1 was able to
totally compete with the binding to 3-DQB1 (lanes 33
and 34). These results suggest that the same protein/s
interact with similar 30UTR nucleotide sequences.
Finally, we assessed that poly(A), poly(C) and poly(G)
homopolymers were unable to compete with the binding
(data not shown), while poly(U) homopolymers were able
to successfully inhibit the formation of both 3-DRA and
3-DQA1protein complexes (Figure 2A, lanes 16, 17, 19
and 20), indicating that the interacting proteins belong
to the class of U-rich binding proteins.
Two known RNA binding proteins, DRBP76/NF90 and
EBP1, are included in the RNP complex interacting
with 30UTR of MHCII mRNAs
We ﬁrst puriﬁed the proteins included in the complex
between S100 Raji extract and 30UTR of MHCII
mRNAs by sequential fractionation using afﬁnity and
anionic exchange chromatography. Protein identiﬁcation
was carried out by functional binding assay and mass
spectrometry analysis of the proteins separated through
SDS–PAGE. In detail, the S100 fraction from Raji cells
was processed by afﬁnity with a column of heparin-
sepharose. Retained proteins were eluted by a KCl discon-
tinuous gradient and fractions collected were analysed by
REMSA. All the samples tested, except the ﬂow-through,
showed RNA binding activity (data not shown). Two
major protein peaks (indicated as a and b in Figure 3,
panel A) were evident in the proﬁle. After dialysis,
pooled fractions from either a or b peaks were further
puriﬁed using FPLC Mono-Q sepharose anion-exchange
chromatography. Proteins were eluted using a linear
gradient of NaCl (Figure 3, panel B) and their binding
activity was tested by northwestern blot. This assay
shows that two fractions from peak b (fractions 37 and
56) exhibited signiﬁcant binding activity (Figure 4, panel
A) with both 3-DRA and 3-DRB1 riboprobes. There were
no fractions from peak a that showed any binding activity
with either riboprobes (data not shown). Both fractions 37
and 56 are composed of several proteins, but 3-DRA and
3-DRB1 probes identiﬁed the same proteins in the pool
(see coomassie gel in panel B of Figure 4). In fraction 37,
one binding protein with an apparent molecular weight
of 50 KDa is detected by both probes, and in fraction
Figure 1. 30UTR of MHC II mRNAs-binding by northwestern. (A)
Schematic representation of HLA-DRA, HLA-DRB1, HLA-DQA1
and HLA-DQB1 mRNAs with 50UTR, coding region and 30UTR
indicated respectively as black, white and grey bars. The probes used
are indicated. (B) Northwestern blot analysis of S100 extracts prepared
from M14 and Raji cell lines carried out with 3-DRA, 3-DRB1 and
3-DQA1 riboprobes. The molecular weights are indicated.
Nucleic Acids Research, 2011,Vol.39, No. 16 726756 one protein of 76 KDa mass. These two proteins were
trypsin digested, extracted from the polyacrylamide gel
and analysed by nano-ESI-MS/MS for identiﬁcation. As
shown in Table 2, the 50 KDa protein was identiﬁed as
EBP1 through the overall sequencing of 14 peptides, while
the 76 KDa protein turned out to be DRBP76/NF90
(three peptides, Table 2). No other peptides were identiﬁed
from these bands, except for those deriving from the
trypsin used for digestion. After probe stripping,
northwestern membranes were used for western blot
with anti-EBP1- and anti-DRBP76-speciﬁc antibodies
and the identity of both proteins was conﬁrmed
(Figure 4, panel C).
Likewise, the 50 KDa protein was also obtained after
sequential puriﬁcation using a ﬁrst step of poly(U)-
sepharose afﬁnity chromatography followed by Mono Q
anion-exchange chromatography. The protein showed
a clear RNA binding activity using northwestern
assay and was identiﬁed as EBP1 by nano-ESI-MS/MS
analysis (data not shown).
To further conﬁrm that EBP1 and DRBP76/NF90 are
components of RNP complex binding to MHCII mRNAs,
we carried out a supershift assay on non-denaturing gel
using antibody against EBP1 or DRBP76. Both 3-DRA
(lanes 6–8, Figure 5, panel A) and 3-DQA1 (lanes 11–13)
riboprobes showed a slower electrophoretic mobility band
Figure 2. 30UTR of MHC II mRNAs binding by REMSA. (A) REMSAs experiments performed using 3-DRA (lane 1) and 3-DQA1 (lane 3)
riboprobes; lanes 2 and 4 show the digestion of riboprobes with T1 RNase. Lanes 5 and 15 show bands of interaction of M14 extract with 3-DRA,
lanes 10 and 18 with 3-DQA1; competition experiments of 3-DRA binding were performed using cold 3-DRA (lanes 6 and 7), cold 3-DQA1 (lanes 8
and 9) and poly(U) homopolymers (lanes 16 and 17). Competition experiments of 3-DQA1 binding were performed using cold 3-DRA (lanes 11 and
12), cold 3-DQA1 (13 and 14) and poly(U) homopolymers (lanes 19 and 20). (B) REMSAs experiments carried out using 3-DRB1 (lane 21) and
3-DQB1 (lane 22) riboprobes. Lanes 22 and 24 show the digestion of riboprobes with T1 RNase; lanes 27 and 32 show bands of interaction of
M14 extract with 3-DRB1 and 3-DQB1.Competition experiments of 3-DRB1 binding were performed using cold 3-DRA (lane 25 and 26) and
cold 3-DQA1 (28 and 29). Competition experiments of 3-DQB1 binding were performed using cold 3-DRA (lanes 30 and 31) and cold 3-DQA1
(33 and 34).
7268 Nucleic Acids Research, 2011,Vol.39, No. 16when anti-DRBP76 antibody was added to the reaction,
compared to the effect of IgG control antibody (lanes 9
and 14). However, retardation of complex mobility was
not detected using anti-EBP1 antibody, probably due to
RNA masking of the EBP1 interaction with speciﬁc
antibody. To sort out this problem and to further
validate the involvement of EBP1 protein in the RNP
complex, we produced recombinant EBP1 protein (28)
whose identity was conﬁrmed by western blot with
anti-EBP1 antibody. The puriﬁed EBP1 protein (data
not shown) or total Escherichia coli extract expressing
the recombinant protein was used in a northwestern
binding assay that further demonstrated the interaction
between the EBP1 and the four riboprobes. The NW
performed with 3-DRB1 demonstrate absence of binding
with a non-related RNA binding protein (31) (Figure 5,
panel C).
Knockdown of EBP1 and DRBP76/NF90 indicates
that they have a role in the accumulation of
MHCII mRNAs
We used siRNAs speciﬁcally interfering with the expres-
sion of EBP1 and DRBP76/NF90 (Table 1) in M14 cells
to establish whether or not the silencing of these
two proteins affects the amount of MHCII molecules.
The knockdown of proteins was checked after 48h by
western blot with speciﬁc antibodies (Figure 6, panel A).
We measured the cell surface HLA-DR expression by ﬂow
cytometry after 72h of transfection and observed a reduc-
tion of 60% mean ﬂuorescence intensity (MFI) after EBP1
silencing and of 45% MFI following DRBP76/NF90
silencing (Figure 6, panel B).
Next, we looked at MHCII-speciﬁc mRNA accumula-
tion by qRT–PCR to establish at which level EBP1 and
DRBP76/NF90 silencing interferes with the cell surface
expression of these molecules. We measured the copy
number of HLA-DRA, HLA-DRB1, HLA-DQA1
mRNAs at 24, 48 and 72h, respectively, after transfection
of cells with speciﬁc siEBP1 and with control siRNA
(siCtrl); the results at 48h are shown in Figure 6, panel
C, as fold of mRNA variation. Following the EBP1
knockdown, we observed a fold change of 0.67±0.03,
0.49±0.02 and 0.45±0.04 for DRA, DRB1 and total
DQA1, respectively. As control for the speciﬁcity of
silencing, we examined the expression of a group of
genes related to our system, the HLA-A-B-C genes (33)
and one totally unrelated gene, Tbx1 (34). In both cases,
we observed no change in the accumulation of their tran-
scripts. This result clearly indicates that the EBP1
silencing induces a decrease in the accumulation of total
MHCII mRNAs. We then looked at MHCII-speciﬁc
Figure 3. Chromatograms of two-step puriﬁcation of MHCII binding proteins. (A) Elution proﬁle of the heparin-sepharose chromatography.
The column was loaded with S100 Raji extract, washed and eluted with KCl discontinuous gradient. (B) Elution proﬁle of the Mono Q chroma-
tography. The column was loaded with the pooled fractions of peak b of the heparin-sepharose column, washed and eluted with a NaCl linear
gradient. On the x-axis is indicated the fraction number, on the primary y-axis the absorbance at 280nm, on the secondary y-axis the concentration
of elution buffers, for both panels.
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oligo used (35) targets a sequence at exon 18 of the gene
and selectively reduced only two isoforms of RNA coding
for NF90 proteins without affecting the other isoforms
(including those coding for NF110). We measured the
copy number of MHCII mRNAs and control messengers;
the results obtained after 48h of transfection are shown in
Figure 6, panel D, as fold of mRNA decrease. We
obtained a fold change of 0.57±0.008, 0.52±0.01 and
0.4±0.04 for DRA, DRB1 and DQA1, respectively, after
NF90 silencing. Similarly to EBP1, this result indicates
that the NF90 reduction induces a decrease in the accu-
mulation of all MHCII mRNAs. To eliminate the possi-
bility that the effect observed on MHCII expression
consequent to the knockdown of the two proteins was
due to a more general effect on the cell cycle progression,
we analysed M14 cells after transfection with either siEbp1
and siNF90 by PI labelling and ﬂow cytometry. We did
not observe any changes in the cell cycle proﬁle (data not
shown).
Cytoplasmic co-regulation of a- and b-mRNAs
Having demonstrated that EBP1 and NF90 interact with
similar binding sites on different MHCII messengers, our
aim was to investigate the possibility of a co-regulation of
HLA-DRA and HLA-DRB1-speciﬁc mRNAs in the cyto-
plasm. We used siRNAs targeting HLA-DRA and
HLA-DRB1 mRNAs (siDRA and siDRB1, respectively,
Table 1) to individually reduce each messenger level in
M14. In cells transfected with siDRA we observed, after
72h, a decrease of 50% of HLA-DR surface expression
compared to the untreated cells, as measured by MFI
(Figure 7, panel A). When we carried out a time course
of DRA mRNA variation, by qRT–PCR, we observed a
progressive decrease with a fold change of 0.87±0.017 at
72h after the transfection (Figure 7, panel Bi), compared
to the untreated cells. Surprisingly, after siDRA transfec-
tion, we also observed a signiﬁcant delayed decrease of
DRB1 mRNA, already apparent at 24h with a fold vari-
ation of 0.2±0.005 and culminating at 72h with a fold
change of 0.86±0.01 (Figure 7, panel Bii).
Likewise, following siDRB1 transfection, we observed a
decrease of 50% of HLA-DR heterodimer expression
(Figure 7, panel A) corresponding to a fold change of
HLA-DRB1-speciﬁc mRNA of 0.79±0.01, after 72h
(Figure 7, panel Cii). When we looked at HLA-DRA
mRNA accumulation, we observed, also in this experi-
ment, an important decrease of transcript already
apparent at 48h with a fold change of 0.22±0.01 and
reaching 0.81±0.02 at 72h compared to the expression
in untreated cells (Figure 7, panel Ci). Our data conﬁrm
that the speciﬁc silencing of the mRNA encoding one
chain of the heterodimer induces the diminution of the
other mRNA, with a delay of 24h. This result indicates
that the amount of one mRNA is related to the quantity of
the other messenger and that they could be co-regulated in
their cytoplasmic processing.
Figure 4. Identiﬁcation of RNA binding proteins. (A) Northwestern blot analysis performed with 3-DRA probe and 3-DRB1 of Raji cell extracts
after Mono Q chromatography. The lanes indicated with numbers 37 and 56 represent the fractions showing the binding; the identiﬁed proteins are
indicated. The molecular weight markers are shown in the middle. (B) SDS–PAGE analysis of heparin-sepharose pool b, indicated as H(b) and of
fractions 37 and 56. The gel was stained with coomassie blue. (C) western blot analysis with anti-EBP1 and anti-DRBP76 antibodies, after stripping
the membranes analysed by northwestern blot.
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The life cycle of an mRNA is thoroughly regulated by its
dynamic association with mRNA binding proteins
(RBPs). In the nucleus, transcripts are capped, spliced,
cleaved and polyadenylated and are subject to a quality
control so that only properly processed molecules are
exported to the cytoplasm, where mRNAs are exposed
to multiple fates including subcellular localization, trans-
lation and degradation (36). These steps were traditionally
thought to occur independently, but several studies have
revealed that many functionally related transcripts
undergo a coupling between transcription and RNA pro-
cessing (37).
In this article, we identiﬁed two proteins, EBP1 and
DRP76/NF90, which bind the 30UTR of MHCII
mRNAs modulating their quantities and consequently
cell surface expression of HLA class II molecules. We
demonstrate that some MHCII mRNAs are subjected to
a co-regulation and probably are connected inside an
‘RNA operon’, including several protein factors that
take part in all transcriptional and post-transcriptional
events of mRNA life.
Previous data from our lab showed a modulation of the
MHC II gene expression at the stability level (14,15), while
the nucleo-cytoplasm export of transcripts was correlated
with the binding of 30UTRs of HLA-DRA and
HLA-DQA1 mRNAs to Raji cytoplasmic factors (16).
In this article, we show that the same sequences also
interact with proteins present in the cytoplasmic extracts
from M14, an MHCII-positive melanoma cell line,
indicating that the binding activity is not tissue speciﬁc.
The nature of the binding activity with 3-DRB1 and
3-DQB1 probes is somewhat different and the interaction
of these riboprobes to factors from M14 cytoplasm
became apparent in REMSA experiments when RNA se-
quences are folded in the correct structure. In addition our
data show that 3-DRA, 3-DQA, 3-DRB1 and 3-DQB1
riboprobes cross-compete for the same protein interaction,
suggesting the presence of two or more similar binding
sites. To unravel the identity of the proteins, we carried
out two subsequent steps of biochemical puriﬁcation using
S100 Raji cytoplasmic extracts, since this is a B cell line
derived from a professional APC. Following northwestern
blot, that allows us to select the bands interacting with
Figure 5. Analysis of RNPs. (A) Supershift of complex with anti-DRBP76 in REMSA performed with 3-DRA (lane 1) and 3-DQA1 probes (lane 3).
Lanes 2 and 4 show the digestion of riboprobes with T1 RNase. Lane 5 shows the interaction of M14 extract with 3-DRA probe while lanes 6–8
clearly show the gel mobility retardation of the complex, in binding reaction containing 0.5, 2 and 6mg of anti-DRBP76 antibody. No supershift was
found in the presence of 6mg of control IgG (lane 9). In the same way, the binding of 3-DQA1 probe was performed in the absence of antibody
(lane 10) or in the presence of 0.5, 2 and 6mg of anti-DRBP76 antibody (lanes 11–13). No supershift was found in the presence of 6mg of control IgG
(lane 14). (B) Analysis of E. coli protein extract expressing recombinant EBP1. C represents the coomassie of SDS–PAGE, WB is the western blot
performed with anti-EBP1, NW are the northwestern blot carried out with indicated riboprobes. (C) Analysis of E. coli protein extract expressing
recombinant EBP1 (Lane 1). C represents the coomassie of SDS–PAGE, NW is the northwestern blot carried out with 3-DRB1 riboprobe. In lane 2
is loaded hnRNPH1 protein.
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identiﬁed two proteins corresponding to 50 and 90 KDa as
EBP1 and DRBP76/NF90, respectively.
EBP1 is the human homologue of the mouse cell
cycle-regulated protein p38-2G4 (38), initially identiﬁed
as an ErbB3 binding protein. Many papers have suggested
that the shorter form of EBP1, p42 acts as a potent
tumour suppressor in various human cancers, whereas
the longer form p48 might function as an oncogene,
promoting cell survival and proliferation (39,40). In
order to study the function of its interaction with 30UTR
of MHCII mRNAs, we decided to speciﬁcally knock
down EBP1. Our results showed a signiﬁcant decrease of
HLA-DRA, HLA-DRB1 and HLA-DQA1 messengers
while other non-correlated transcripts were unaffected.
This result suggests that EBP1 may play a function at
the transcriptional and/or post-transcriptional level, con-
sidering that literature data seem to indicate a double role
for EBP1. This protein, indeed, is able to recruit a tran-
scriptional repressor complex including the histone
deacetilase 2 (HDAC2), the retinoblastoma protein (Rb)
and Sin3A corepressor (41–43). Since other evidence has
indicated that, in some tumour cells, the MHCII tran-
scriptional repression occurs by the inhibition of the
CIITA transactivator function, through the recruitment
of HDAC1/2 and Sin3A in presence or not of Rb
protein (44), we speculate that EBP1 could bind the re-
pressor complex (Rb/HDAC/Sin3A), reducing its negative
transcriptional effect on MHCII genes. This mechanism
could regulate the conversion of cancer cells to antigen
presenting cells and consequently could induce tumour
antigen presentation (45).
On the other hand, the down-regulation of MHCII
mRNAs, following EBP1 depletion, can also be explained
by a mechanism modulating the messenger stability, as
already demonstrated for BCL2 mRNA (46). Zhou et al.
(47) have instead conﬁrmed the capability of EBP1 to
promote the androgen receptor (AR), mRNA decay
through the interaction with a UC-rich motif within the
30UTR. The crystal structure (28) and the other literature
data (48) indicate that EBP1 may bind structured RNAs
as IREs (49) and ribosomal RNA, thereby enhancing
translation initiation, as well as ssRNA, dsRNA and
dsDNA (28). Finally, in the cytoplasm, EBP1 has been
found in association with 80S ribosomes and polysomes,
consistent with a role in the control of the translation
process (28,50).
The other protein interacting with MHCII mRNAs
identiﬁed in our study is DRBP76 (51), a member of the
dsRNA binding proteins (DRBP) family capable of
binding both dsRNAs and highly structured single-
stranded RNA molecules (52) through its C-terminus
region. Differential splicing gives rise to two different mo-
lecular weight protein isoforms and the proteins homolo-
gous to DRBP76 with 90 KDa molecular weight are
named NF90 and NFAR1(53).
Literature data indicate that NF90 recognizes the
antigen receptor response element (ARRE)/nuclear
factor of activated T cell (NFAT) motifs on DNA and
mediates the activation of IL-2 transcription in response
to T cell receptor stimulation (54). In THP1 and HeLa
cells, NF90 binds to the DNase I Hypersensitive site II
(DHS-II) in the ﬁrst intron of the HLA-DRA gene (55);
nevertheless the interaction and the consequent modula-
tion of transcription seems to be strictly correlated to the
activation status of the cells. Through its association with
the 30UTRs of different mRNAs, DRBP76/NF90 can in-
ﬂuence the nucleus–cytoplasm export (56) or the stability
Figure 6. Modulation of MHCII expression following knockdown of EBP1 and DRBP76/NF90 proteins in M14 cells. (A) Western blot analysis of
cell extracts after silencing of two proteins using siEBP1 and siNF90, performed with anti-EBP1, anti-DRBP76 and anti-a tubulin antibodies. (B)
Flow cytometry analysis of cells transfected with siEBP1, siNF90 and siCtrl and stained with HLA-DR speciﬁc antibodies. Results are plotted as fold
change of MFI (mean ﬂuorescence intensity) value. (C) qRT–PCR analysis of total mRNAs after silencing with either siCtrl or siEBP1. The graph
illustrates the mRNA fold variation of the transcripts indicated on the x-axis. (D) qRT–PCR analysis of total mRNAs following silencing with either
siCtrl or siNF90. The graph illustrates the mRNA fold variation of the transcripts indicated on the x-axis. The standard deviations are shown in all
graphs.
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DRBP76/NF90 leads to a subsequent inhibition of trans-
lation rates (35) that may also constitute an innate
immune translational surveillance mechanism in host
defence against virus infection (56,59).
In this article, we show that the speciﬁc silencing of
DRBP76/NF90 in the M14 cell line induces a decrease
in MHCII mRNA accumulation. Similarly to EBP1,
DRBP76/NF90 could down-regulate the MHCII tran-
scription or affect the stability of the MHCII messengers.
We can speculate a co-transcriptional recruitment of the
mRNAs by DRBP76/NF90 that can interact with the
ﬁrst intron of unspliced mRNA or with its 30UTR
determining, either a transcriptional regulation or, a
post-transcriptional modulation, in terms of export or sta-
bility messenger. The balance between the two mechan-
isms may be a consequence of the cell’s need to express
MHCII and to present antigen during the immune
response, both in professional or non-professional APC.
Our data indicate that all MHCII mRNAs encoding a-
and b-chains of HLA-DR and HLA-DQ isotypes bind
both EBP1 and DRBP76/NF90 proteins (probably by a
dsRNA secondary structure, such as a stem–loop)
common to different transcripts, carrying an U-rich
sequence. Moreover, since the speciﬁc knockdown of
DRA or DRB1 mRNAs inﬂuences the accumulation of
the other messenger, we propose that both messengers
could be associated inside a RNP complex with each
other and co-regulated during the cytoplasmic processing.
It appears that EBP1 knockdown does not affect
DRBP76/NF90 protein expression, nor does DRBP76/
NF90 silence EBP1; the depletion of each protein is not
able to completely annul the MHCII mRNA accumula-
tion, suggesting a cooperative role. One mechanism could
Figure 7. Downregulation of MHCII expression following knockdown of DRA or DRB1 mRNAs in M14 cells. (A) Flow cytometry analysis of the
cell line transfected with and siCtrl, siDRA and siDRB1 and stained with HLA-DR-speciﬁc antibodies. Results are plotted as fold change of MFI
(mean ﬂuorescence intensity) value. (B) qRT–PCR analysis of total mRNAs following silencing with siDRA and siCtrl, analysed at different times
after transfection. The B(i) panel shows HLA-DRA mRNA fold variation and the B(ii) shows HLA-DRB1 mRNA fold variation. (C) qRT–PCR
analysis of total mRNAs following silencing with siDRB1 and siCtrl, analysed at different times after transfection. The C(i) panel shows HLA-DRA
mRNA fold variation and C(ii) HLA-DRB1 mRNA fold variation. The standard deviations are shown in all graphs.
Nucleic Acids Research, 2011,Vol.39, No. 16 7273be the interaction of RNA binding proteins to different
but similar binding sites, the depletion of one protein
being partially compensated by the other.
We speculate that both proteins are joined to the same
RNP complex, as occurs for the complex binding BCL2
mRNA (46) probably in association with other factors, to
regulate MHCII expression in relationship to different
biological pathways and in this framework it is not
surprising that EBP1 and DRBP76/NF90 seem to
achieve the same effect on MHCII mRNAs. Both
proteins could function in cooperation to couple tran-
scriptional and post-transcriptional events and to guaran-
tee a co-regulated expression of all mRNAs inside the
functional unit of the ‘MHC class II operon’, during the
adaptive immune response.
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